← Leaderboards
Dennis L. Kasper
Harvard Medical School
$33,539,979
Attributed
$33,539,979
Total exposure
22
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $16.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$172,457,123 · 24
By mechanism
U54$124,692,822 · 7
U19$30,617,347 · 3
R01$8,327,195 · 4
T32$4,790,637 · 1
N01$2,075,207 · 3
R21$906,121 · 2
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Emily Patricia Balskus$9,130,479
- Sungwhan F Oh$5,178,148
- Joon Seok Park$211,846
- Christophe O Benoist$53,813,482
Others in their field
Top investigators on “Pathogen”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$343,790,695
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
- Jeffrey P Krischer · University Of South Florida$130,496,919
- Mark S Klempner · Tufts Medical Center$128,021,180
- Timothy Stedman · American Type Culture Collection$122,230,581
- Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai$99,962,183
Research focus
PathogenVaccinesBaseCellsVaccine DevelopmentOrganismImmunityPolysaccharidesGlycoconjugatesResearch PersonnelAntibodiesCarbohydratesProteinsAnimal ModelProductionPathway InteractionsImmunizationInnovationImmune ResponseDesignProgramsCommunicable DiseasesFrancisella TularensisPeptides
Grant awards (93)
Gut complement system: Induction and protection against enteric infection$790,356
R01 · FY2025 · AI · contact PI
Tetraacylated lipid A enhancement of checkpoint blocking cancer immunotherapy$198,103
R21 · FY2025 · CA · contact PI
Elucidating the Structural Requirements for Next-Gen Glycoconjugate Vaccines$613,070
R01 · FY2024 · AI · contact PI
Tetraacylated lipid A enhancement of checkpoint blocking cancer immunotherapy$237,724
R21 · FY2024 · CA · contact PI
Elucidating the Structural Requirements for Next-Gen Glycoconjugate Vaccines$613,070
R01 · FY2023 · AI · contact PI
Elucidating the Structural Requirements for Next-Gen Glycoconjugate Vaccines$604,595
R01 · FY2022 · AI · contact PI
Elucidating the Structural Requirements for Next-Gen Glycoconjugate Vaccines$604,595
R01 · FY2021 · AI · contact PI
Elucidating the Structural Requirements for Next-Gen Glycoconjugate Vaccines$604,595
R01 · FY2020 · AI · contact PI
Innovative Platforms for Antimicrobial Therapy and Vaccine Development$4,685,717
U19 · FY2018 · AI · contact PI
Rationally designed platform for enhanced glycoconjugate vaccines$619,244
U19 · FY2018 · AI · contact PI
Administrative Core$241,788
U19 · FY2018 · AI · contact PI
Innovative Platforms for Antimicrobial Therapy and Vaccine Development$5,183,191
U19 · FY2017 · AI · contact PI
Administrative Core$741,666
U19 · FY2017 · AI · contact PI
Rationally designed platform for enhanced glycoconjugate vaccines$619,257
U19 · FY2017 · AI · contact PI
Innovative Platforms for Antimicrobial Therapy and Vaccine Development$5,474,214
U19 · FY2016 · AI · contact PI
Rationally designed platform for enhanced glycoconjugate vaccines$1,039,366
U19 · FY2016 · AI · contact PI
Administrative Core$235,959
U19 · FY2016 · AI · contact PI
Innovative Platforms for Antimicrobial Therapy and Vaccine Development$4,932,536
U19 · FY2015 · AI · contact PI
Rationally designed platform for enhanced glycoconjugate vaccines$619,417
U19 · FY2015 · AI · contact PI
Knowledge-based Vaccines Built on Paradigm Changes in Antigen Presentation$423,750
R01 · FY2015 · AI · contact PI
Administrative Core$249,133
U19 · FY2015 · AI · contact PI
Innovative Platforms for Antimicrobial Therapy and Vaccine Development$4,937,887
U19 · FY2014 · AI · contact PI
Rationally designed platform for enhanced glycoconjugate vaccines$790,737
U19 · FY2014 · AI · contact PI
Knowledge-based Vaccines Built on Paradigm Changes in Antigen Presentation$423,750
R01 · FY2014 · AI · contact PI
Administrative Core$247,235
U19 · FY2014 · AI · contact PI
New England Regional Center of Excellence in Biodefense and Emerging Infectious D$9,785,208
U54 · FY2013 · AI · contact PI
Administrative Core$990,300
U54 · FY2013 · AI · contact PI
Developmental Projects$508,286
U54 · FY2013 · AI · contact PI
Knowledge-based Vaccines Built on Paradigm Changes in Antigen Presentation$397,934
R01 · FY2013 · AI · contact PI
Development of a conjugate vaccine for the prevention of tularemia$384,395
U54 · FY2013 · AI · contact PI
New England Regional Center of Excellence in Biodefense and Emerging Infectious D$11,042,365
U54 · FY2012 · AI · contact PI
Developmental Projects$828,037
U54 · FY2012 · AI · contact PI
Administrative Core$773,455
U54 · FY2012 · AI · contact PI
Development of a conjugate vaccine for the prevention of tularemia$404,291
U54 · FY2012 · AI · contact PI
Knowledge-based Vaccines Built on Paradigm Changes in Antigen Presentation$214,640
R01 · FY2012 · AI · contact PI
Knowledge-based Vaccines Built on Paradigm Changes in Antigen Presentation$209,044
R01 · FY2012 · AI · contact PI
Commensal Bacteroides signal through sphingolipid rafts during intestinal stress$153,488
R21 · FY2012 · AI · contact PI
Commensal Bacteroides signal through sphingolipid rafts during intestinal stress$61,393
R21 · FY2012 · AI · contact PI
New England Regional Center of Excellence in Biodefense and Emerging Infectious D$10,375,910
U54 · FY2011 · AI · contact PI
Developmental Projects$772,196
U54 · FY2011 · AI · contact PI
Administrative Core$755,576
U54 · FY2011 · AI · contact PI
Infectious Disease and Basic Microbiological Mechanisms$497,655
T32 · FY2011 · AI · contact PI
Development of a conjugate vaccine for the prevention of tularemia$475,987
U54 · FY2011 · AI · contact PI
Knowledge-based Vaccines Built on Paradigm Changes in Antigen Presentation$428,019
R01 · FY2011 · AI · contact PI
Commensal Bacteroides signal through sphingolipid rafts during intestinal stress$255,413
R21 · FY2011 · AI · contact PI
Infectious Disease and Basic Microbiological Mechanisms$114,097
T32 · FY2011 · AI · contact PI
New England Regional Center of Excellence in Biodefense and Emerging Infectious D$10,622,077
U54 · FY2010 · AI · contact PI
Administrative Core$744,160
U54 · FY2010 · AI · contact PI
Developmental Projects$688,393
U54 · FY2010 · AI · contact PI
Development of a conjugate vaccine for the prevention of tularemia$493,122
U54 · FY2010 · AI · contact PI
Infectious Disease and Basic Microbiological Mechanisms$234,413
T32 · FY2010 · AI · contact PI
Development of a conjugate vaccine for the prevention of tularemia$34,527
U54 · FY2010 · AI · contact PI
New England Regional Center of Excellence in Biodefense and Emerging Infectious D$34,527
U54 · FY2010 · AI · contact PI
New England Regional Center of Excellence in Biodefense and Emerging Infectious D$10,756,628
U54 · FY2009 · AI · contact PI
New England Regional Center of Excellence in Biodefense and Emerging Infectious D$3,365,340
U54 · FY2009 · AI · contact PI
Developmental Projects$705,179
U54 · FY2009 · AI · contact PI
Administrative Core$673,653
U54 · FY2009 · AI · contact PI
Development of a conjugate vaccine for the prevention of tularemia$543,504
U54 · FY2009 · AI · contact PI
Infectious Disease and Basic Microbiological Mechanisms$299,322
T32 · FY2009 · AI · contact PI
New England Regional Center of Excellence for Biodefens*$10,425,237
U54 · FY2008 · AI · contact PI
Administrative Core$744,998
U54 · FY2008 · AI · contact PI
Development of a Conjugate Vaccine for the Prevention of Tularemia$469,164
U54 · FY2008 · AI · contact PI
Infectious Disease and Basic Microbiological Mechanisms$463,208
T32 · FY2008 · AI · contact PI
New England Regional Center of Excellence for Biodefense$10,253,895
U54 · FY2007 · AI · contact PI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$390,666
T32 · FY2007 · AI · contact PI
PATHOGENIC MECHANISMS OF ANAEROBES IN SEPSIS$365,619
R01 · FY2007 · AI · contact PI
PREVENTION OF GROUP B STREPTOCOCCAL (GBS) DISEASE$250,000
N01 · FY2007 · AI · contact PI
New England Regional Center of Excellence for Biodefens*$10,436,968
U54 · FY2006 · AI · contact PI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$468,999
T32 · FY2006 · AI · contact PI
PATHOGENIC MECHANISMS OF ANAEROBES IN SEPSIS$376,539
R01 · FY2006 · AI · contact PI
PREVENTION OF GROUP B STREPTOCOCCAL /GBS/ DISEASE-266025495-266025495$0
N01 · FY2006 · AI · contact PI
New England Regional Center of Excellence for Biodefens*$10,609,215
U54 · FY2005 · AI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$407,608
T32 · FY2005 · AI
PATHOGENIC MECHANISMS OF ANAEROBES IN SEPSIS$385,600
R01 · FY2005 · AI
STRUCTURE OF BACTERIAL POLYSACCHARIDES AND THE DEGREE OF IGG SWITCH ASSOCIATION$33,521
P51 · FY2005 · RR
New England Regional Center of Excellence for Biodefens*$11,843,830
U54 · FY2004 · AI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$465,111
T32 · FY2004 · AI
PATHOGENIC MECHANISMS OF ANAEROBES IN SEPSIS$385,600
R01 · FY2004 · AI
STRUCTURE OF BACTERIAL POLYSACCHARIDES$35,475
P51 · FY2004 · RR
New England Regional Center of Excellence for Biodefense$4,152,399
U54 · FY2003 · AI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$437,779
T32 · FY2003 · AI
PATHOGENIC MECHANISMS OF ANAEROBES IN SEPSIS$192,800
R01 · FY2003 · AI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$381,698
T32 · FY2002 · AI
IMMUNOCHEMISTRY OF GROUP B STREPTOCOCCAL POLYSACCHARIDES$426,573
R37 · FY2001 · AI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$400,526
T32 · FY2001 · AI
PATHOGENIC MECHANISMS OF ANAEROBES IN SEPSIS$351,937
R01 · FY2001 · AI
THE STREPTOCOCCAL INITIATIVE$1,825,207
N01 · FY2000 · AI
IMMUNOCHEMISTRY OF GROUP B STREPTOCOCCAL POLYSACCHARIDES$414,150
R37 · FY2000 · AI
PATHOGENIC MECHANISMS OF ANAEROBES IN SEPSIS$341,682
R01 · FY2000 · AI
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS$229,555
T32 · FY2000 · AI
CELL HARVESTER &MULTILABEL COUNTER$133,075
S10 · FY2000 · RR
9TH INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES$5,000
R13 · FY2000 · AI
THE STREPTOCOCCAL INITIATIVE$0
N01 · FY2000 · AI